Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The randomized trials which include ACOSOG Z0011 and IBCSG 23-01 had found that the survival rates were not different in patients with cT1/2N0 and 1-2 sentinel lymph node (SLN)-positive, macro/micrometastases who underwent breast-conserving therapy, and micrometastases who underwent total mastectomy (TM), when axillary lymph node dissection (ALND) was omitted. However, for patients with cT1/2N0 and 1-2 SLN macrometastases who underwent TM; there was still insufficient evidence from clinical studies to support whether ALND can be exempted. This study aimed to investigate the risk factors of non-sentinel lymph node (nSLN) metastasis in breast cancer patients with 1-2 SLN macrometastases undergoing TM.
Methods: The clinicopathological data of 1491 breast cancer patients who underwent TM and SLNB from January 2017 to February 2022 were retrospectively analyzed. Univariate and multivariate analyses were performed to analyze the risk factors for nSLN metastasis.
Results: A total of 273 patients with 1-2 SLN macrometastases who underwent TM were enrolled. Postoperative pathological data showed that 35.2% patients had nSLN metastasis. The results of multivariate analysis indicated that tumor size (TS) (P = 0.002; OR: 1.051; 95% CI: 1.019-1.084) and ratio of SLN macrometastases (P = 0.0001; OR: 12.597: 95% CI: 4.302-36.890) were the independent risk factors for nSLN metastasis in breast cancer patients with 1-2 SLN macrometastases that underwent TM. The ROC curve analysis suggested that when TS ≤22 mm and ratio of SLN macrometastases ≤0.33, the incidence of nSLN metastasis could be reduced to 17.1%.
Conclusions: The breast cancer patients with cT1/2N0 stage, undergoing TM and 1-2 SLN macrometastases, when the TS ≤22 mm and macrometastatic SLN does not exceed 1/3 of the total number of detected SLN, the incidence of nSLN metastasis is significantly reduced, but whether ALND can be exempted needs further exploration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077622 | PMC |
| http://dx.doi.org/10.1186/s12957-023-02888-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Additional Axillary Disease After Neoadjuvant Chemotherapy for Patients with Clinically Node-Negative but Sentinel Node-Positive Disease.
Ann Surg Oncol
August 2025
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Background: Axillary lymph node dissection (ALND) is associated with considerable risk of arm morbidity. This study aimed to identify risk factors for additional disease found at ALND in patients with a diagnosis of clinically node-negative (cN0) breast cancer who had sentinel lymph node (SLN) metastasis after neoadjuvant chemotherapy (NACT) as a help to identify patients for whom ALND may be safely omitted.
Methods: This retrospective national cohort study analyzed Danish patients with a diagnosis of cT1-3 breast cancer and cN0 disease from October 2016 to November 2022 but a positive SLN biopsy after NACT.
Identifying low-volume metastases through ultrastaging of negative pelvic nodes in recurrent early-stage cervical cancer: a case series and literature review.
Eur J Obstet Gynecol Reprod Biol
July 2025
Department of Obstetrics and Gynaecology, 'Filippo Del Ponte' Hospital, University of Insubria, Varese, Italy.
Introduction: Ultrastaging has been shown to improve the detection of macrometastases (MACs), micrometastases (MICs) and isolated tumour cells (ITCs). This study evaluated the role of ultrastaging in the management of cervical cancer through a single-centre retrospective analysis, along with a systematic literature review.
Methods: This retrospective study included patients surgically treated for FIGO 2009 stage IA1-IB1 cervical cancer between January 2011 and December 2023 with negative lymph nodes and no adjuvant therapy based on tumour risk factors.
Survival disparities in women with endometrial cancer based on metastasis size in the sentinel lymph node: A tertiary cancer centre observational cohort study.
Eur J Obstet Gynecol Reprod Biol
August 2025
Department of Gynaecological Oncology, Royal Marsden Hospital, 203 Fulham Rd., London SW3 6JJ, United Kingdom. Electronic address:
Background: The adoption of sentinel lymph node (SLN)-mapping with ultrastaging for patients with endometrial cancer has led to increased rates of metastatic nodal disease due to the detection of low-volume metastases (LVM), i.e. micrometastasis and isolated tumour cells (ITCs).
View Article and Find Full Text PDFExploring isolated tumor cells entity in endometrial cancer.
Eur J Cancer
July 2025
Department of Gynecology and Obstetrics, University Hospital of Parma, Italy.
Background: Endometrial cancer (EC) management includes nodal staging and molecular classification. Despite molecular advancements, the biological significance of isolated tumor cells (ITC) in EC remains unclear. This study aimed to characterize ITC in the context of pathological and molecular features MATERIALS AND METHODS: A multicenter, retrospective analysis included EC patients diagnosed between June 2018 and May 2024 who underwent surgical staging via sentinel lymph node (SLN) biopsy and molecular profiling.
View Article and Find Full Text PDFBackground In breast cancer surgery, sentinel lymph node biopsy (SLNB) is routinely utilized for axillary assessment. Frozen section examination of the sentinel lymph node (SLN) is used to guide the decision for axillary dissection. Adjuvant treatment is also planned based on the final pathological examination of the axilla and the mastectomy/breast-conserving surgery specimen.
View Article and Find Full Text PDF